Roche/Genentech will join Parent Project Muscular Dystrophy for a webinar on Wednesday, May 16 at 1:00 PM EDT to provide an update on their Anti-Myostatin Adnectin (RG6206) development program.
You will learn more about the team at Roche and its US affiliate, Genentech, and how they are collaborating with the Duchenne community. The team will also update you on their Anti-Myostatin Adnectin (RG6206) program, including the status of ongoing clinical studies.
- Pat Furlong
Founding President & CEO
Parent Project Muscular Dystrophy
- Sangeeta Jethwa
Head, Patient Partnership, Rare Diseases, Basel, Switzerland
- Michelle Krishnan
Translational Medicine Leader, Basel, Switzerland
- J.P. Sacksteder
Alliance & Advocacy Relations, Government Affairs, San Francisco
- Michael Solomonides
Operations Program Leader, UK
Please submit questions in advance to firstname.lastname@example.org (subject line: Roche/Genentech Webinar) by Monday, May 14 at 12pm eastern.